- Method for the preparation of high purity Rosuvastatin Calcium salt
-
The present invention relates to a method for manufacturing a Rosuvastatin calcium salt by using a Rosuvastatin tert-butyl amine salt, and to a method for manufacturing a high purity Rosuvastatin calcium salt, which has impurities less than 0.1% of a diastereomer. The manufacturing method of a high purity Rosuvastatin calcium salt comprises the steps of: 1) manufacturing a compound represented by chemical formula III by reducing a compound represented by chemical formula IV; 2) manufacturing a compound represented by chemical formula II by adding t-butyl amine; and 3) manufacturing a compound represented by chemical formula I by adding a calcium ion to the compound represented by chemical formula II.COPYRIGHT KIPO 2016
- -
-
-
- An Asymmetric Synthesis of Rosuvastatin Calcium
-
A novel asymmetric synthesis of a (3R,5S)-dihydroxyhexanoic ester is described. The ester, which serves as the precursor for generating the side chain of rosuvastatin, is synthesized from d-glucose and subsequently coupled, under Wittig olefination condit
- Vempala, Naresh,Venkateswara Rao, Settipalli,Shree, Anireddy Jaya,Pradhan, Braja S.
-
p. 4167 - 4174
(2016/11/26)
-
- AMINE SALTS OF PITAVASTATIN AND ROSUVASTATIN
-
The present invention relates to oxygen-comprising amine salts of HMG-CoA reductase inhibitors, to a method of producing said amine salts and to the use of said amine salts in the production of pharmaceutically acceptable salts of HMG-CoA reductase inhibi
- -
-
Page/Page column 16; 17
(2014/10/15)
-
- AMINE SALTS OF PRAVASTATIN AND ROSUVASTATIN
-
The present invention relates to unsaturated amine salts of HMG-CoA reductase inhibitors, to a method of producing said amine salts and to the use of said amine salts in the production of pharmaceutically acceptable salts of HMG-CoA reductase inhibitors.
- -
-
Page/Page column 15; 16
(2014/10/15)
-
- NOVEL INTERMEDIATES FOR THE PREPARATION OF HMG-CoA REDUCTASE INHIBITORS
-
The present invention provides a process for preparing novel intermediates of Formula wherein, R1 can be hydrogen, C1-C4 alkyl, halogen, nitro, hydroxy, or C1-C4 alkoxy; Rx can be selected from hydrophobic residue of HMG-CoA reductase inhibitors; which can be effectively used for the preparation of HMG-CoA reductase inhibitors such as rosuvastatin and pharmaceutically acceptable salts thereof.
- -
-
-
- METHOD FOR PREPARING ROSUVASTATIN SALTS
-
The present invention is related to methods for the preparation of pharmaceutically acceptable salts of (+)-7-[4-(4-fluorophenyl)-6- isopropyl-2-(methanesulfonyl-methyl-amino)-pyrimidin-5-yl]-(3R, 5S, 6E)-dihydroxy-hept-6-enoic acid, intermediates thereof
- -
-
-
- METHOD FOR THE PREPARATION OF HIGH-PURITY PHARMACEUTICAL INTERMEDIATES
-
The present invention is related to intermediates useful in the preparation of pharmceutically acceptable salts of (+)-7-[4-(4- fluorophenyl)-6-isopropyl-2-(methanesulfonyl-methyl-amino)- pyrimidin-5-yl]-(3R,5S)-dihydroxy-hept-6-enoic acid and polymorphs
- -
-
Page/Page column 52
(2012/06/16)
-
- A PROCESS FOR THE PREPARATION OF ROSUVASTATIN CALCIUM
-
The present invention relates to a novel, industrially viable and cost effective process for preparation of bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino] pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid] calcium salt, comm
- -
-
Page/Page column 9-10
(2011/10/13)
-
- PROCESS FOR THE PREPARATION OF ROSUVASTATIN
-
The invention relates to a process for the preparation of a HMG - CoA reductase inhibitor such as rosuvastatin, as well as intermediates useful in such process. The invention also relates to salts of HMG-CoA reductase inhibitors and processes for preparing same as well as processes for preparing pharmaceutically acceptable salts of HMG-CoA reductase inhibitors.
- -
-
Page/Page column 53-54
(2010/08/08)
-
- NOVEL PROCESS FOR THE PREPARATION OF STATINS AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF
-
Novel process for the preparation of statins and their pharmaceutically acceptable salts thereof represented by the general formula-(1) through novel intermediate compounds of general formula-(4).
- -
-
Page/Page column 44-45
(2008/06/13)
-
- NOVEL PROCESS FOR STATINS AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF
-
Novel process for statins and its pharmaceutically acceptable salts thereof represented by general formula (I).
- -
-
Page/Page column 61; 80-81
(2008/06/13)
-
- PROCESS FOR PREPARING AMORPHOUS ROSUVASTATIN CALCIUM FREE OF IMPURITIES
-
A pure amorphous form of rosuvastatin calcium having purity of more than 99.5%, preferably a purity of more than 99.8%, more preferably a purity of more than 99.9% as determined by HPLC area percentage, and free from any traces of alkali metal impurities is disclosed. A process of preparing said pure amorphous form of rosuvastatin calcium is disclosed, which comprises hydrolysis of C1-C5 alkyl esters of rosuvastatin, preferably terf-butyl ester of rosuvastatin, with an organic nitrogen base, e.g. guanidines, amidines, amines and quaternary ammonium hydroxides, in the presence of water, optionally containing aprotic solvent, following the conversion of thus obtained rosuvastain salt with a source of calcium to desired rosuvastatin calcium, which is then isolated. An alternative process is disclosed, which comprises the conversion of numerous novel ammonium salts of rosuvastatin, preferably tert-octylammonium salt of rosuvastatin, with the source of calcium to desired commercial rosuvastatin calcium.. Rosuvastatin calcium is HMG CoA reductase, useful in the treatment of hyperlipidemia, hypercholesterolemia and atherosclerosis.
- -
-
Page/Page column 13-14; 15-16
(2008/06/13)
-